The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research.
touchRESPIRATORY were delighted to talk to PFF Vice President, Junelle Speller around the unmet needs in the treatment of pulmonary fibrosis and interstitial lung disease, and the PFF Registry and Community Registry.
- What are the unmet needs in the treatment of pulmonary fibrosis (PF) and interstitial lung disease (ILD)? (2:14)
- Could you give a brief overview of the Pulmonary Fibrosis Foundation (PFF) Patient Registry and the PFF Community Registry? (3:55)
Disclosures: Junelle Speller has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
To find out more visit the website here.
Share this Video
Related Videos In Interstitial Lung Disease
Clinical trials and current standard of care in idiopathic pulmonary fibrosis: Steven D. Nathan, ATS 2023
Idiopathic pulmonary fibrosis (IPF) is a serious chronic lung disease which results in symptoms such as shortness of breath and dry cough and is caused by fibrosis of the lungs. It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) to discuss the incidence, prognosis and pathology of […]
TETON-1 & -2 phase 3 studies of treprostinil in IPF – baseline characteristics: Steven D. Nathan, ATS 2023
The TETON program consists of two currently recruiting phase 3 randomized, double-blind, placebo-controlled studies that are investigating the efficacy and safety of inhaled treprostinil in idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) around the aims and design of the TETON program […]
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!